Cargando…

Relating protease inhibitor resistance at time of virological failure with drug exposure

Detalles Bibliográficos
Autores principales:	Van Luin, M, Bannister, WP, Paredes, R, Phillips, AN, Bruun, J, Van Lunzen, J, Kirk, O, d'Arminio Monforte, A, Cozzi-Lepri, A, Burger, DM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112893/ http://dx.doi.org/10.1186/1758-2652-13-S4-P118

Ejemplares similares

Reply to Manfredi
por: Lichtner, Miriam, et al.
Publicado: (2015)

Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice
por: Costarelli, Silvia, et al.
Publicado: (2014)

Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?
por: d’Arminio Monforte, Antonella, et al.
Publicado: (2020)

Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure
por: Schultze, Anna, et al.
Publicado: (2014)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Illness Representations of HIV Positive Patients Are Associated with Virologic Success
por: Leone, Daniela, et al.
Publicado: (2016)

Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe
por: Zoufaly, Alexander, et al.
Publicado: (2014)

Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort
por: d’Arminio Monforte, Antonella, et al.
Publicado: (2016)

Immunologic characterization of a patient with clinical and virologic rebound upon Nirmatrelvir/Ritonavir treatment: the unfortunate epilogue of COVID-19
por: Marchetti, Giulia, et al.
Publicado: (2023)

Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort
por: Cingolani, A, et al.
Publicado: (2015)

Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort
por: Saracino, Annalisa, et al.
Publicado: (2014)

Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy
por: Bandera, Alessandra, et al.
Publicado: (2015)

Increased incidence of sexually transmitted diseases in the recent years: data from the ICONA cohort
por: Cingolani, Antonella, et al.
Publicado: (2014)

Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study
por: Marchetti, Giulia, et al.
Publicado: (2014)

Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort
por: Nozza, Silvia, et al.
Publicado: (2017)

Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study
por: Mussini, Cristina, et al.
Publicado: (2018)

Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?
por: Shanyinde, Milensu, et al.
Publicado: (2019)

T-Cell Phenotypes, Apoptosis and Inflammation in HIV+ Patients on Virologically Effective cART with Early Atherosclerosis
por: Merlini, Esther, et al.
Publicado: (2012)

Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus
por: Mussini, Cristina, et al.
Publicado: (2015)

Circulating sCD14 Is Associated with Virological Response to Pegylated-Interferon-Alpha/Ribavirin Treatment in HIV/HCV Co-Infected Patients
por: Marchetti, Giulia, et al.
Publicado: (2012)

Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration
por: Touloumi, Giota, et al.
Publicado: (2013)

Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice
por: Costarelli, Silvia, et al.
Publicado: (2016)

Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV
por: Merlini, Esther, et al.
Publicado: (2021)

Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss
por: Mussini, Cristina, et al.
Publicado: (2021)

Correction to: Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV
por: Merlini, Esther, et al.
Publicado: (2021)

Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort
por: Di Biagio, Antonio, et al.
Publicado: (2014)

Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

CD4 cell count and the risk of infective and non-infective serious non-AIDS events in HIV-positive persons seen for care in Italy
por: Madeddu, Giordano, et al.
Publicado: (2014)

HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients
por: Saracino, Annalisa, et al.
Publicado: (2018)

Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort
por: Mondi, Annalisa, et al.
Publicado: (2019)

HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients
por: Malagnino, Vincenzo, et al.
Publicado: (2020)

Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study
por: Spaziante, Martina, et al.
Publicado: (2021)

Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U era
por: Madeddu, Giordano, et al.
Publicado: (2021)

Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders
por: Giancola, Maria Letizia, et al.
Publicado: (2012)

Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population
por: Cingolani, Antonella, et al.
Publicado: (2017)

Predictors of virological failure in HIV‐1‐infected patients switching to dolutegravir maintenance monotherapy
por: Wijting, IEA, et al.
Publicado: (2018)

Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor–Based Regimen: The “STORE” Study
por: Gori, Andrea, et al.
Publicado: (2020)

Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature
por: Tincati, Camilla, et al.
Publicado: (2018)

Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy
por: Di Biagio, Antonio, et al.
Publicado: (2016)

Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting
por: Gianotti, Nicola, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9tnvs0qr30fujeel7k8v4fdtvb